Stem cell therapy for the systemic right ventricle

References

• Wallis GA, Debich-Spicer D, Anderson RH. Congenitally corrected transposition. Orphanet J Rare Dis. 2011;6:22.
   PubMed Web of Science ®Google Scholar
• Graham TP Jr., Bernard YD, Mellen BG, et al. Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. J Am Coll Cardiol. 2000;36(1):255–261.
   PubMed Web of Science ®Google Scholar
• Alghamdi AA, McCrindle BW, Van Arsdell GS. Physiologic versus anatomic repair of congenitally corrected transposition of the great arteries: meta-analysis of individual patient data. Ann Thorac Surg. 2006;81(4):1529–1535.
   PubMed Web of Science ®Google Scholar
• Lim HG, Lee JR, Kim YJ, et al. Outcomes of biventricular repair for congenitally corrected transposition of the great arteries. Ann Thorac Surg. 2010;89(1):159–167.
   PubMed Web of Science ®Google Scholar
• Horer J, Schreiber C, Krane S, et al. Outcome after surgical repair/palliation of congenitally corrected transposition of the great arteries. Thorac Cardiovasc Surg. 2008;56(7):391–397.
   PubMed Web of Science ®Google Scholar
• Bautista-Hernandez V, Myers PO, Cecchin F, et al. Late left ventricular dysfunction after anatomic repair of congenitally corrected transposition of the great arteries. J Thorac Cardiovasc Surg. 2014;148(1):254–258.
   PubMed Web of Science ®Google Scholar
• Quinn DW, McGuirk SP, Metha C, et al. The morphologic left ventricle that requires training by means of pulmonary artery banding before the double-switch procedure for congenitally corrected transposition of the great arteries is at risk of late dysfunction. J Thorac Cardiov Sur. 2008;135(5):1137–U1122.
   PubMed Web of Science ®Google Scholar
• Villafane J, Lantin-Hermoso MR, Bhatt AB, et al. D-transposition of the great arteries: the current era of the arterial switch operation. J Am Coll Cardiol. 2014;64(5):498–511.
   PubMed Web of Science ®Google Scholar
• Warnes CA, Somerville J. Transposition of the great arteries: late results in adolescents and adults after the Mustard procedure. Br Heart J. 1987;58(2):148–155.
   PubMedGoogle Scholar
• Okuda H, Nakazawa M, Imai Y, et al. Comparison of ventricular function after Senning and Jatene procedures for complete transposition of the great arteries. Am J Cardiol. 1985;55(5):530–534.
   PubMed Web of Science ®Google Scholar
• Roos-Hesselink JW, Meijboom FJ, Spitaels SE, et al. Decline in ventricular function and clinical condition after Mustard repair for transposition of the great arteries (a prospective study of 22-29 years). Eur Heart J. 2004;25(14):1264–1270.
   PubMed Web of Science ®Google Scholar
• Morris CD, Outcalt J, Menashe VD. Hypoplastic left heart syndrome: natural history in a geographically defined population. Pediatrics. 1990;85(6):977–983.
   PubMed Web of Science ®Google Scholar
• Samanek M, Slavik Z, Zborilova B, et al. Prevalence, treatment, and outcome of heart disease in live-born children: a prospective analysis of 91,823 live-born children. Pediatr Cardiol. 1989;10(4):205–211.
   PubMed Web of Science ®Google Scholar
• Fyler DC, Rothman KJ, Buckley LP, et al. The determinants of five year survival of infants with critical congenital heart disease. Cardiovasc Clin. 1981;11(2):393–405.
   PubMedGoogle Scholar
• Norwood WI, Lang P, Hansen DD. Physiologic repair of aortic atresia-hypoplastic left heart syndrome. N Engl J Med. 1983;308(1):23–26.
   PubMed Web of Science ®Google Scholar
• Gewillig M, Brown SC, Eyskens B, et al. The Fontan circulation: who controls cardiac output? Interact Cardiovasc Thorac Surg. 2010;10(3):428–433.
   PubMed Web of Science ®Google Scholar
• d’Udekem Y, Iyengar AJ, Galati JC, et al. Redefining expectations of long-term survival after the Fontan procedure: twenty-five years of follow-up from the entire population of Australia and New Zealand. Circulation. 2014;130(11Suppl 1):S32–38.
   PubMed Web of Science ®Google Scholar
• Iyengar AJ, Winlaw DS, Galati JC, et al. The extracardiac conduit Fontan procedure in Australia and New Zealand: hypoplastic left heart syndrome predicts worse early and late outcomes. Eur J Cardiothorac Surg. 2014;46(3):465-473;discussion 473.
   Web of Science ®Google Scholar
• Arnold RR, Loukanov T, Gorenflo M. Hypoplastic left heart syndrome - unresolved issues. Front Pediatr. 2014;2:125.
   PubMed Web of Science ®Google Scholar
• Tham EB, Smallhorn JF, Kaneko S, et al. Insights into the evolution of myocardial dysfunction in the functionally single right ventricle between staged palliations using speckle-tracking echocardiography. J Am Soc Echocardiogr. 2014;27(3):314–322.
   PubMed Web of Science ®Google Scholar
• Kaneko S, Khoo NS, Smallhorn JF, et al. Single right ventricles have impaired systolic and diastolic function compared to those of left ventricular morphology. J Am Soc Echocardiogr. 2012;25(11):1222–1230.
   PubMed Web of Science ®Google Scholar
• Kutty S, Graney BA, Khoo NS, et al. Serial assessment of right ventricular volume and function in surgically palliated hypoplastic left heart syndrome using real-time transthoracic three-dimensional echocardiography. J Am Soc Echocardiogr. 2012;25(6):682–689.
   PubMed Web of Science ®Google Scholar
• Sundareswaran KS, Kanter KR, Kitajima HD, et al. Impaired power output and cardiac index with hypoplastic left heart syndrome: a magnetic resonance imaging study. Ann Thorac Surg. 2006;82(4):1267-1275;discussion 1275-1267.
   PubMed Web of Science ®Google Scholar
• Bernstein D. Introduction to the series: challenges and opportunities in pediatric heart failure and transplantation. Circulation. 2014;129(1):112–114.
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Simon RGJ. The changing landscape of pulmonary arterial hypertension and implications for patient care. Eur Respir Rev. 2014;23(134):450–457.
   PubMedGoogle Scholar
• van de Veerdonk MC, Bogaard HJ, Voelkel NF. The right ventricle and pulmonary hypertension. Heart Fail Rev. 2016;21(3):259–271.
   PubMed Web of Science ®Google Scholar
• Borgdorff MA, Dickinson MG, Berger RM, et al. Right ventricular failure due to chronic pressure load: what have we learned in animal models since the NIH working group statement? Heart Fail Rev. 2015;20(4):475–491.
   PubMed Web of Science ®Google Scholar
• Wehman B, Kaushal S. The emergence of stem cell therapy for patients with congenital heart disease. Circ Res. 2015;116(4):566–569.
   PubMed Web of Science ®Google Scholar
• Rodemoyer A, Kibiryeva N, Bair A, et al. A tissue-specific gene expression template portrays heart development and pathology. Hum Genomics. 2014;8:6.
   PubMed Web of Science ®Google Scholar
• Tabibiazar R, Wagner RA, Liao A, et al. Transcriptional profiling of the heart reveals chamber-specific gene expression patterns. Circ Res. 2003;93(12):1193–1201.
   PubMed Web of Science ®Google Scholar
• Hudlicka O, Brown M, Egginton S. Angiogenesis in skeletal and cardiac-muscle. Physiol Rev. 1992;72(2):369–417.
   PubMed Web of Science ®Google Scholar
• Souders CA, Borg TK, Banerjee I, et al. Pressure overload induces early morphological changes in the heart. Am J Pathol. 2012;181(4):1226–1235.
   PubMed Web of Science ®Google Scholar
• Tomanek RJ, Torry RJ. Growth of the coronary vasculature in hypertrophy: mechanisms and model dependence. Cell Mol Biol Res. 1994;40(2):129–136.
   PubMedGoogle Scholar
• Kai H, Mori T, Tokuda K, et al. Pressure overload-induced transient oxidative stress mediates perivascular inflammation and cardiac fibrosis through angiotensin II. Hypertens Res. 2006;29(9):711–718.
   PubMed Web of Science ®Google Scholar
• Sag CM, Santos CX, Shah AM. Redox regulation of cardiac hypertrophy. J Mol Cell Cardiol. 2014;73:103–111.
   PubMed Web of Science ®Google Scholar
• Reddy S, Bernstein D. The vulnerable right ventricle. Curr Opin Pediatr. 2015;27(5):563–568.
   PubMed Web of Science ®Google Scholar
• Drake JI, Bogaard HJ, Mizuno S, et al. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol. 2011;45(6):1239–1247.
   PubMed Web of Science ®Google Scholar
• Padalino MA, Castellani C, Toffoli S, et al. Pathological changes and myocardial remodelling related to the mode of shunting following surgical palliation for hypoplastic left heart syndrome. Cardiol Young. 2008;18(4):415–422.
   PubMed Web of Science ®Google Scholar
• Salih C, Sheppard MN, Ho SY. Morphometry of coronary capillaries in hypoplastic left heart syndrome. Ann Thorac Surg. 2004;77(3):903–907.
   PubMed Web of Science ®Google Scholar
• Ryan JJ, Archer SL. The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure. Circ Res. 2014;115(1):176–188.
   PubMed Web of Science ®Google Scholar
• Sutendra G, Dromparis P, Paulin R, et al. A metabolic remodeling in right ventricular hypertrophy is associated with decreased angiogenesis and a transition from a compensated to a decompensated state in pulmonary hypertension. J Mol Med. 2013;91(11):1315–1327.
   PubMed Web of Science ®Google Scholar
• Potus F, Ruffenach G, Dahou A, et al. Downregulation of MicroRNA-126 contributes to the failing right ventricle in pulmonary arterial hypertension. Circulation. 2015;132(10):932–943.
   PubMed Web of Science ®Google Scholar
• Ruiter G, Ying Wong Y, de Man FS, et al. Right ventricular oxygen supply parameters are decreased in human and experimental pulmonary hypertension. J Heart Lung Transplant. 2013;32(2):231–240.
   PubMed Web of Science ®Google Scholar
• Weber KT, Clark WA, Janicki JS, et al. Physiologic versus pathologic hypertrophy and the pressure-overloaded myocardium. J Cardiovasc Pharmacol. 1987;10(Suppl 6):S37–50.
   PubMedGoogle Scholar
• Tocchetti CG, Gallucci G, Coppola C, et al. The emerging issue of cardiac dysfunction induced by antineoplastic angiogenesis inhibitors. Eur J Heart Fail. 2013;15(5):482–489.
   PubMed Web of Science ®Google Scholar
• Ecarnot-Laubriet A, Rochette L, Vergely C, et al. The activation pattern of the antioxidant enzymes in the right ventricle of rat in response to pressure overload is of heart failure type. Heart Dis. 2003;5(5):308–312.
   PubMedGoogle Scholar
• Schreckenberg R, Rebelo M, Deten A, et al. Specific mechanisms underlying right heart failure: the missing upregulation of superoxide dismutase-2 and its decisive role in antioxidative defense. Antioxid Redox Signal. 2015;23(15):1220–1232.
   PubMed Web of Science ®Google Scholar
• Cabigas EB, Ding G, Chen T, et al. Age- and chamber-specific differences in oxidative stress after ischemic injury. Pediatr Cardiol. 2012;33(2):322–331.
   PubMed Web of Science ®Google Scholar
• Qipshidze N, Tyagi N, Metreveli N, et al. Autophagy mechanism of right ventricular remodeling in murine model of pulmonary artery constriction. Am J Physiol Heart Circ Physiol. 2012;302(3):H688–696.
   PubMed Web of Science ®Google Scholar
• Zungu-Edmondson M, Shults NV, Wong CM, et al. Modulators of right ventricular apoptosis and contractility in a rat model of pulmonary hypertension. Cardiovasc Res. 2016;110(1):30–39.
   PubMed Web of Science ®Google Scholar
• Piao L, Marsboom G, Archer SL. Mitochondrial metabolic adaptation in right ventricular hypertrophy and failure. J Mol Med (Berl). 2010;88(10):1011–1020.
   PubMed Web of Science ®Google Scholar
• Acar P, Sidi D, Bonnet D, et al. Maintaining tricuspid valve competence in double discordance: a challenge for the paediatric cardiologist. Heart. 1998;80(5):479–483.
   PubMed Web of Science ®Google Scholar
• Kral Kollars CA, Gelehrter S, Bove EL, et al. Effects of morphologic left ventricular pressure on right ventricular geometry and tricuspid valve regurgitation in patients with congenitally corrected transposition of the great arteries. Am J Cardiol. 2010;105(5):735–739.
   PubMed Web of Science ®Google Scholar
• Dimopoulos S, Anastasiou-Nana M, Katsaros F, et al. Impairment of autonomic nervous system activity in patients with pulmonary arterial hypertension: a case control study. J Card Fail. 2009;15(10):882–889.
   PubMedGoogle Scholar
• Wu C, Guo J, Liu H, et al. The correlation of decreased heart rate recovery and chronotropic incompetence with exercise capacity in idiopathic pulmonary arterial hypertension patients. Biomed Res Int. 2017;3415401:2017.
   Google Scholar
• Giardini A, Lovato L, Donti A, et al. A pilot study on the effects of carvedilol on right ventricular remodelling and exercise tolerance in patients with systemic right ventricle. Int J Cardiol. 2007;114(2):241–246.
   PubMed Web of Science ®Google Scholar
• Josephson CB, Howlett JG, Jackson SD, et al. A case series of systemic right ventricular dysfunction post atrial switch for simple D-transposition of the great arteries: the impact of beta-blockade. Can J Cardiol. 2006;22(9):769–772.
   PubMed Web of Science ®Google Scholar
• van Campen JS, De Boer K, van de Veerdonk MC, et al. Bisoprolol in idiopathic pulmonary arterial hypertension: an explorative study. Eur Respir J. 2016;48(3):787–796.
   PubMed Web of Science ®Google Scholar
• Robinson B, Heise CT, Moore JW, et al. Afterload reduction therapy in patients following intraatrial baffle operation for transposition of the great arteries. Pediatr Cardiol. 2002;23(6):618–623.
   PubMed Web of Science ®Google Scholar
• Hechter SJ, Fredriksen PM, Liu P, et al. Angiotensin-converting enzyme inhibitors in adults after the Mustard procedure. Am J Cardiol. 2001;87(5):660–663, A611.
   PubMed Web of Science ®Google Scholar
• Lester SJ, McElhinney DB, Viloria E, et al. Effects of losartan in patients with a systemically functioning morphologic right ventricle after atrial repair of transposition of the great arteries. Am J Cardiol. 2001;88(11):1314–1316.
   PubMed Web of Science ®Google Scholar
• Dore A, Houde C, Chan KL, et al. Angiotensin receptor blockade and exercise capacity in adults with systemic right ventricles: a multicenter, randomized, placebo-controlled clinical trial. Circulation. 2005;112(16):2411–2416.
   PubMed Web of Science ®Google Scholar
• Friehs I, Barillas R, Vasilyev NV, et al. Vascular endothelial growth factor prevents apoptosis and preserves contractile function in hypertrophied infant heart. Circulation. 2006;114(1 Suppl):I290–295.
   PubMed Web of Science ®Google Scholar
• Hoenig MR, Bianchi C, Rosenzweig A, et al. The cardiac microvasculature in hypertension, cardiac hypertrophy and diastolic heart failure. Curr Vasc Pharmacol. 2008;6(4):292–300.
   PubMed Web of Science ®Google Scholar
• Li W, Xiang AP. Safeguarding clinical translation of pluripotent stem cells with suicide genes. Organogenesis. 2013;9(1):34–39.
   PubMed Web of Science ®Google Scholar
• Ben-David U, Benvenisty N. The tumorigenicity of human embryonic and induced pluripotent stem cells. Nat Rev Cancer. 2011;11(4):268–277.
   PubMed Web of Science ®Google Scholar
• Lv FJ, Tuan RS, Cheung KM, et al. Concise review: the surface markers and identity of human mesenchymal stem cells. Stem Cells. 2014;32(6):1408–1419.
   PubMed Web of Science ®Google Scholar
• Burlacu A, Grigorescu G, Rosca AM, et al. Factors secreted by mesenchymal stem cells and endothelial progenitor cells have complementary effects on angiogenesis in vitro. Stem Cells Dev. 2013;22(4):643–653.
   PubMed Web of Science ®Google Scholar
• Hung SC, Pochampally RR, Chen SC, et al. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells. 2007;25(9):2363–2370.
   PubMed Web of Science ®Google Scholar
• Bronckaers A, Hilkens P, Martens W, et al. Mesenchymal stem/stromal cells as a pharmacological and therapeutic approach to accelerate angiogenesis. Pharmacol Therapeut. 2014;143(2):181–196.
   PubMed Web of Science ®Google Scholar
• Carrion B, Kong YP, Kaigler D, et al. Bone marrow-derived mesenchymal stem cells enhance angiogenesis via their alpha 6 beta 1 integrin receptor. Exp Cell Res. 2013;319(19):2964–2976.
   PubMed Web of Science ®Google Scholar
• Katare R, Riu F, Rowlinson J, et al. Perivascular delivery of encapsulated mesenchymal stem cells improves postischemic angiogenesis via paracrine activation of VEGF-A. Arterioscl Throm Vas. 2013;33(8):1872–1880.
   Web of Science ®Google Scholar
• Sadat S, Gehmert S, Song YH, et al. The cardioprotective effect of mesenchymal stem cells is mediated by IGF-1 and VEGF. Biochem Bioph Res Co. 2007;363(3):674–679.
   PubMed Web of Science ®Google Scholar
• Dufourcq P, Descamps B, Tojais NF, et al. Secreted frizzled-related protein-1 enhances mesenchymal stem cell function in angiogenesis and contributes to neovessel maturation. Stem Cells. 2008;26(11):2991–3001.
   PubMed Web of Science ®Google Scholar
• Kuchroo P, Dave V, Vijayan A, et al. Paracrine factors secreted by umbilical cord-derived MSCs induce angiogenesis in vitro by a VEGF-independent pathway. Stem Cells Dev. 2015 Feb 15;24(4):437–450. doi: 10.1089/scd.2014.0184.
   Web of Science ®Google Scholar
• Kong P, Xie X, Li F, et al. Placenta mesenchymal stem cell accelerates wound healing by enhancing angiogenesis in diabetic Goto-Kakizaki (GK) rats. Biochem Biophys Res Commun. 2013;438(2):410–419.
   PubMed Web of Science ®Google Scholar
• Rahbarghazi R, Nassiri SM, Khazraiinia P, et al. Juxtacrine and paracrine interactions of rat marrow-derived mesenchymal stem cells, muscle-derived satellite cells, and neonatal cardiomyocytes with endothelial cells in angiogenesis dynamics. Stem Cells Dev. 2013;22(6):855–865.
   PubMed Web of Science ®Google Scholar
• Mohammadi E, Nassiri SM, Rahbarghazi R, et al. Endothelial juxtaposition of distinct adult stem cells activates angiogenesis signaling molecules in endothelial cells. Cell Tissue Res. 2015;362(3):597–609.
   PubMed Web of Science ®Google Scholar
• Shyu KG, Wang BW, Hung HF, et al. Mesenchymal stem cells are superior to angiogenic growth factor genes for improving myocardial performance in the mouse model of acute myocardial infarction. J Biomed Sci. 2006;13(1):47–58.
   PubMed Web of Science ®Google Scholar
• Ikhapoh IA, Pelham CJ, Agrawal DK. Sry-type HMG box 18 contributes to the differentiation of bone marrow-derived mesenchymal stem cells to endothelial cells. Differentiation. 2015;89(3–4):87–96.
   PubMed Web of Science ®Google Scholar
• Qiu X, Zhang Y, Zhao X, et al. Enhancement of endothelial differentiation of adipose derived mesenchymal stem cells by a three-dimensional culture system of microwell. Biomaterials. 2015;53:600–608.
   PubMed Web of Science ®Google Scholar
• Lu W, Xiu X, Zhao Y, et al. Differentiation of bone marrow mesenchymal stem cells into vascular endothelial cells with sphingosine 1-phosphate. Transpl P. 2015;47(6):2035–2040.
   PubMed Web of Science ®Google Scholar
• Konstanty-Kalandyk J, Piatek J, Miszalski-Jamka T, et al. The combined use of transmyocardial laser revascularisation and intramyocardial injection of bone-marrow derived stem cells in patients with end-stage coronary artery disease: one year follow-up. Kardiol Pol. 2013;71(5):485–492.
   PubMed Web of Science ®Google Scholar
• Gupta PK, Chullikana A, Parakh R, et al. A double blind randomized placebo controlled phase I/II study assessing the safety and efficacy of allogeneic bone marrow derived mesenchymal stem cell in critical limb ischemia. J Transl Med. 2013;11:143.
   Web of Science ®Google Scholar
• Mathiasen AB, Haack-Sorensen M, Jorgensen E, et al. Autotransplantation of mesenchymal stromal cells from bone-marrow to heart in patients with severe stable coronary artery disease and refractory angina - Final 3-year follow-up. Int J Cardiol. 2013;170(2):246–251.
   PubMed Web of Science ®Google Scholar
• Lasala GP, Silva JA, Minguell JJ. Therapeutic angiogenesis in patients with severe limb ischemia by transplantation of a combination stem cell product. J Thorac Cardiov Sur. 2012;144(2):377–382.
   PubMed Web of Science ®Google Scholar
• Karantalis V, DiFede DL, Gerstenblith G, et al. Autologous mesenchymal stem cells produce concordant improvements in regional function, tissue perfusion, and fibrotic burden when administered to patients undergoing coronary artery bypass grafting. Circ Res. 2014;114(8):1302–1310.
   PubMed Web of Science ®Google Scholar
• Heldman AW, DiFede DL, Fishman JE, et al. Transendocardial mesenchymal stem cells and mononuclear bone marrow cells for ischemic cardiomyopathy the TAC-HFT randomized trial. Jama-J Am Med Assoc. 2014;311(1):62–73.
   PubMed Web of Science ®Google Scholar
• Hess DC, Sila CA, Furlan AJ, et al. A double-blind placebo-controlled clinical evaluation of MultiStem for the treatment of ischemic stroke. Int J Stroke. 2014;9(3):381–386.
   PubMed Web of Science ®Google Scholar
• George R, Lardo A. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial (vol 308, pg 2369, 2012). JAMA-J Am Med Assoc. 2013;310(7):750–750.
   Web of Science ®Google Scholar
• Lu DB, Chen B, Liang ZW, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double-blind, randomized, controlled trial. Diabetes Res Clin Pr. 2011;92(1):26–36.
   PubMed Web of Science ®Google Scholar
• Wehman B, Sharma S, Pietris N, et al. Mesenchymal stem cells preserve neonatal right ventricular function in a porcine model of pressure overload. Am J Physiol Heart Circ Physiol. 2016;310(11):H1816–1826.
   PubMed Web of Science ®Google Scholar
• Chen XQ, Chen LL, Fan L, et al. Stem cells with FGF4-bFGF fused gene enhances the expression of bFGF and improves myocardial repair in rats. Biochem Biophys Res Commun. 2014;447(1):145–151.
   PubMed Web of Science ®Google Scholar
• Han Y, Tao R, Han Y, et al. Microencapsulated VEGF gene-modified umbilical cord mesenchymal stromal cells promote the vascularization of tissue-engineered dermis: an experimental study. Cytotherapy. 2014;16(2):160–169.
   PubMed Web of Science ®Google Scholar
• HoWangYin KY, Loinard C, Bakker W, et al. HIF-prolyl hydroxylase 2 inhibition enhances the efficiency of mesenchymal stem cell-based therapies for the treatment of critical limb ischemia. Stem Cells. 2014;32(1):231–243.
   PubMed Web of Science ®Google Scholar
• Zhang T, Lee YW, Rui YF, et al. Bone marrow-derived mesenchymal stem cells promote angiogenesis and growth of breast and prostate tumors. Cytotherapy. 2013;15(4):S15–S15.
   Web of Science ®Google Scholar
• Zhao MZ, Nonoguchi N, Ikeda N, et al. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J Cereb Blood Flow Metab. 2006;26(9):1176–1188.
   PubMed Web of Science ®Google Scholar
• Fierro FA, Kalomoiris S, Sondergaard CS, et al. Effects on proliferation and differentiation of multipotent bone marrow stromal cells engineered to express growth factors for combined cell and gene therapy. Stem Cells. 2011;29(11):1727–1737.
   PubMed Web of Science ®Google Scholar
• Huang CY, Gu HM, Yu Q, et al. Sca-1+cardiac stem cells mediate acute cardioprotection via paracrine factor SDF-1 following myocardial ischemia/reperfusion. PloS One. 2011;6(12):e29246.
   Web of Science ®Google Scholar
• Tseliou E, Pollan S, Malliaras K, et al. Allogeneic cardiospheres safely boost cardiac function and attenuate adverse remodeling after myocardial infarction in immunologically mismatched rat strains. J Am Coll Cardiol. 2013;61(10):1108–1119.
   PubMed Web of Science ®Google Scholar
• Cheng K, Malliaras K, Smith RR, et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail. 2014;2(1):49–61.
   PubMed Web of Science ®Google Scholar
• Hou L, Kim JJ, Woo YJ, et al. Stem cell-based therapies to promote angiogenesis in ischemic cardiovascular disease. Am J Physiol Heart Circ Physiol. 2016 Feb 15;310(4):H455–65. doi: 10.1152/ajpheart.00726.2015.
   Google Scholar
• Bader AM, Brodarac A, Klose K, et al. Mechanisms of paracrine cardioprotection by cord blood mesenchymal stromal cells. Eur J Cardiothorac Surg. 2014;45(6):983–992.
   PubMed Web of Science ®Google Scholar
• Nakanishi C, Yamagishi M, Yamahara K, et al. Activation of cardiac progenitor cells through paracrine effects of mesenchymal stem cells. Biochem Biophys Res Commun. 2008;374(1):11–16.
   PubMed Web of Science ®Google Scholar
• Kazakov A, Meier T, Werner C, et al. C-kit(+) resident cardiac stem cells improve left ventricular fibrosis in pressure overload. Stem Cell Res. 2015;15(3):700–711.
   PubMed Web of Science ®Google Scholar
• Agarwal U, Smith AW, French KM, et al. Age-dependent effect of pediatric cardiac progenitor cells after juvenile heart failure. Stem Cells Transl Med. 2016;5(7):883–892.
   PubMed Web of Science ®Google Scholar
• Maeng YS, Kwon JY, Kim EK, et al. Heterochromatin Protein 1 Alpha (HP1alpha: CBX5) is a key regulator in differentiation of endothelial progenitor cells to endothelial cells. Stem Cells. 2015;33(5):1512–1522.
   PubMed Web of Science ®Google Scholar
• Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005;353(10):999–1007.
   PubMed Web of Science ®Google Scholar
• Hoenig MR, Bianchi C, Sellke FW. Hypoxia inducible factor-1 alpha, endothelial progenitor cells, monocytes, cardiovascular risk, wound healing, cobalt and hydralazine: a unifying hypothesis. Curr Drug Targets. 2008;9(5):422–435.
   PubMed Web of Science ®Google Scholar
• Moon JH, Chae MK, Kim KJ, et al. Decreased endothelial progenitor cells and increased serum glycated albumin are independently correlated with plaque-forming carotid artery atherosclerosis in type 2 diabetes patients without documented ischemic disease. Circ J. 2012;76(9):2273–2279.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Miorin M, Facco M, et al. Circulating endothelial progenitor cells are reduced in peripheral vascular complications of type 2 diabetes mellitus. J Am Coll Cardiol. 2005;45(9):1449–1457.
   PubMed Web of Science ®Google Scholar
• Lee FY, Chen YL, Sung PH, et al. Intracoronary transfusion of circulation-derived cd34+ cells improves left ventricular function in patients with end-stage diffuse coronary artery disease unsuitable for coronary intervention. Crit Care Med. 2015;43(10):2117–2132.
   PubMed Web of Science ®Google Scholar
• Atluri P, Miller JS, Emery RJ, et al. Tissue-engineered, hydrogel-based endothelial progenitor cell therapy robustly revascularizes ischemic myocardium and preserves ventricular function. J Thorac Cardiovasc Surg. 2014;148(3):1090-1097;discussion 1097-1098.
   Web of Science ®Google Scholar
• Oommen S, Yamada S, Peral SC, et al. Human umbilical cord blood-derived mononuclear cells improve murine ventricular function upon intramyocardial delivery in right ventricular chronic pressure overload. Stem Cell Res Ther. 2015;6:50.
   Web of Science ®Google Scholar
• Yang Z, von Ballmoos MW, Faessler D, et al. Paracrine factors secreted by endothelial progenitor cells prevent oxidative stress-induced apoptosis of mature endothelial cells. Atherosclerosis. 2010;211(1):103–109.
   PubMed Web of Science ®Google Scholar
• Cheng Y, Guo S, Liu G, et al. Transplantation of bone marrow-derived endothelial progenitor cells attenuates myocardial interstitial fibrosis and cardiac dysfunction in streptozotocin-induced diabetic rats. Int J Mol Med. 2012;30(4):870–876.
   PubMed Web of Science ®Google Scholar
• Qiu J, Li W, Feng S, et al. Transplantation of bone marrow-derived endothelial progenitor cells attenuates cerebral ischemia and reperfusion injury by inhibiting neuronal apoptosis, oxidative stress and nuclear factor-kappaB expression. Int J Mol Med. 2013;31(1):91–98.
   PubMed Web of Science ®Google Scholar
• Lob HE, Marvar PJ, Guzik TJ, et al. Induction of hypertension and peripheral inflammation by reduction of extracellular superoxide dismutase in the central nervous system. Hypertension. 2010;55(2):277–283, 276p following 283.
   PubMed Web of Science ®Google Scholar
• Laurila JP, Laatikainen LE, Castellone MD, et al. SOD3 reduces inflammatory cell migration by regulating adhesion molecule and cytokine expression. PloS One. 2009;4(6):e5786.
   PubMed Web of Science ®Google Scholar
• Rabbani ZN, Anscher MS, Folz RJ, et al. Overexpression of extracellular superoxide dismutase reduces acute radiation induced lung toxicity. BMC Cancer. 2005;5:59.
   PubMed Web of Science ®Google Scholar
• DeSantiago J, Bare DJ, Banach K. Ischemia/Reperfusion injury protection by mesenchymal stem cell derived antioxidant capacity. Stem Cells Dev. 2013;22(18):2497–2507.
   PubMed Web of Science ®Google Scholar
• Arslan F, Lai RC, Smeets MB, et al. Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. Stem Cell Res. 2013;10(3):301–312.
   PubMed Web of Science ®Google Scholar
• Pan Q, Qin X, Ma S, et al. Myocardial protective effect of extracellular superoxide dismutase gene modified bone marrow mesenchymal stromal cells on infarcted mice hearts. Theranostics. 2014;4(5):475–486.
   PubMed Web of Science ®Google Scholar
• Pisano A, Cerbelli B, Perli E, et al. Impaired mitochondrial biogenesis is a common feature to myocardial hypertrophy and end-stage ischemic heart failure. Cardiovasc Pathol. 2016;25(2):103–112.
   PubMed Web of Science ®Google Scholar
• Plotnikov EY, Khryapenkova TG, Vasileva AK, et al. Cell-to-cell cross-talk between mesenchymal stem cells and cardiomyocytes in co-culture. J Cell Mol Med. 2008;12(5a):1622–1631.
   Web of Science ®Google Scholar
• Zhang Y, Yu Z, Jiang D, et al. iPSC-MSCs with high intrinsic MIRO1 and sensitivity to TNF-alpha yield efficacious mitochondrial transfer to rescue anthracycline-induced cardiomyopathy. Stem Cell Rep. 2016;7(4):749–763.
   PubMed Web of Science ®Google Scholar
• Jeevanantham V, Butler M, Saad A, et al. Adult bone marrow cell therapy improves survival and induces long-term improvement in cardiac parameters: a systematic review and meta-analysis. Circulation. 2012;126(5):551–568.
   PubMed Web of Science ®Google Scholar
• Zimmet H, Porapakkham P, Porapakkham P, et al. Short- and long-term outcomes of intracoronary and endogenously mobilized bone marrow stem cells in the treatment of ST-segment elevation myocardial infarction: a meta-analysis of randomized control trials. Eur J Heart Fail. 2012;14(1):91–105.
   PubMed Web of Science ®Google Scholar
• Fisher SA, Doree C, Mathur A, et al. Meta-analysis of cell therapy trials for patients with heart failure. Circ Res. 2015;116(8):1361–1377.
   PubMed Web of Science ®Google Scholar
• Gyongyosi M, Wojakowski W, Lemarchand P, et al. Meta-analysis of cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res. 2015;116(8):1346–1360.
   PubMed Web of Science ®Google Scholar
• Patel AN, Henry TD, Quyyumi AA, et al. Ixmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. Lancet. 2016;387(10036):2412–2421.
   PubMed Web of Science ®Google Scholar
• Perin EC, Borow KM, Silva GV, et al. A Phase II dose-escalation study of allogeneic mesenchymal precursor cells in patients with ischemic or nonischemic heart failure. Circ Res. 2015;117(6):576–584.
   PubMed Web of Science ®Google Scholar
• Mathiasen AB, Qayyum AA, Jorgensen E, et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J. 2015;36(27):1744–1753.
   PubMed Web of Science ®Google Scholar
• Hare JM, DiFede DL, Castellanos AM, et al. Randomized comparison of allogeneic vs. autologous mesenchymal stem cells for non-ischemic dilated cardiomyopathy: POSEIDON-DCM trial. J Am Coll Cardiol. 2017 Feb 7;69(5):526–537. doi: 10.1016/j.jacc.2016.11.009.
   Web of Science ®Google Scholar
• Ascheim DD, Gelijns AC, Goldstein D, et al. Mesenchymal precursor cells as adjunctive therapy in recipients of contemporary left ventricular assist devices. Circulation. 2014;129(22):2287–2296.
   PubMed Web of Science ®Google Scholar
• Hare JM, Fishman JE, Gerstenblith G, et al. Comparison of allogeneic vs autologous bone marrow-derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. Jama. 2012;308(22):2369–2379.
   PubMed Web of Science ®Google Scholar
• Bergmane I, Lacis A, Lubaua I, et al. Follow-up of the patients after stem cell transplantation for pediatric dilated cardiomyopathy. Pediatr Transplant. 2013;17(3):266–270.
   PubMed Web of Science ®Google Scholar
• Rupp S, Bauer J, Tonn T, et al. Intracoronary administration of autologous bone marrow-derived progenitor cells in a critically ill two-yr-old child with dilated cardiomyopathy. Pediatr Transplant. 2009;13(5):620–623.
   PubMed Web of Science ®Google Scholar
• Rupp S, Zeiher AM, Dimmeler S, et al. A regenerative strategy for heart failure in hypoplastic left heart syndrome: intracoronary administration of autologous bone marrow-derived progenitor cells. J Heart Lung Transplant. 2010;29(5):574–577.
   PubMed Web of Science ®Google Scholar
• Tarui S, Sano S, Oh H. Stem cell therapies in patients with single ventricle physiology. Methodist Debakey Cardiovasc J. 2014;10(2):77–81.
   PubMedGoogle Scholar
• Malliaras K, Makkar RR, Smith RR, et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol. 2014;63(2):110–122.
   PubMed Web of Science ®Google Scholar
• Bolli R, Chugh AR, D’Amario D, et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet. 2011;378(9806):1847–1857.
   PubMed Web of Science ®Google Scholar
• Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res. 2015;116(4):653–664.
   PubMed Web of Science ®Google Scholar
• Burkhart HM, Qureshi MY, Peral SC, et al. Regenerative therapy for hypoplastic left heart syndrome: first report of intraoperative intramyocardial injection of autologous umbilical-cord blood-derived cells. J Thorac Cardiovasc Surg. 2015;149(3):e35–37.
   PubMed Web of Science ®Google Scholar
• Jasmin, De Souza GT, Louzada RA, et al. Tracking stem cells with superparamagnetic iron oxide nanoparticles: perspectives and considerations. Int J Nanomed. 2017;12:779–793.
   PubMedGoogle Scholar
• Fukushima S, Sawa Y, Suzuki K. Choice of cell-delivery route for successful cell transplantation therapy for the heart. Future Cardiol. 2013;9(2):215–227.
   PubMedGoogle Scholar
• Fischer UM, Harting MT, Jimenez F, et al. Pulmonary passage is a major obstacle for intravenous stem cell delivery: the pulmonary first-pass effect. Stem Cells Dev. 2009;18(5):683–691.
   PubMed Web of Science ®Google Scholar
• Vrtovec B, Poglajen G, Lezaic L, et al. Comparison of transendocardial and intracoronary CD34+ cell transplantation in patients with nonischemic dilated cardiomyopathy. Circulation. 2013;128(11 Suppl 1):S42–49.
   PubMed Web of Science ®Google Scholar
• Ishida O, Hagino I, Nagaya N, et al. Adipose-derived stem cell sheet transplantation therapy in a porcine model of chronic heart failure. Transl Res. 2015;165(5):631–639.
   PubMed Web of Science ®Google Scholar
• Hamdi H, Planat-Benard V, Bel A, et al. Epicardial adipose stem cell sheets results in greater post-infarction survival than intramyocardial injections. Cardiovasc Res. 2011;91(3):483–491.
   PubMed Web of Science ®Google Scholar
• Fisher SA, Doree C, Mathur A, et al. Stem cell therapy for chronic ischaemic heart disease and congestive heart failure. Cochrane Database Syst Rev. 2016;12:CD007888.
   PubMedGoogle Scholar
• Suen CM, Zhai A, Lalu MM, et al. Efficacy and safety of regenerative cell therapy for pulmonary arterial hypertension in animal models: a preclinical systematic review protocol. Syst Rev. 2016;5:89.
   PubMedGoogle Scholar